This is especially true for some women with polyendocrine metabolic ovarian syndrome (PMOS), a condition marked by irregular periods or absent ovulation
Research has identified these alarming vision-related risks associated with GLP-1 medications: Sudden irreversible vision loss: NAION strikes without warning, often discovered upon waking, causing blurry or dim vision that progresses to immediate and permanent partial or complete blindness in the affected eye with no possibility of restoration Elevated risk across multiple studies: Beyond the Harvard findings showing 4-7 fold increased risk, a University of Southern Denmark study examining over 424,000 patients found weekly semaglutide users faced 2.19 times higher NAION risk European regulatory recognition: In June 2025, the European Medicines Agency officially recognized NAION as a possible side effect of semaglutide medications, marking formal acknowledgment by international regulators Complete absence of treatment options: Medical science currently offers no cure, no effective treatment, and no way to reverse NAION-related vision damage, leaving patients with permanent disability The permanent and irreversible nature of NAION-related optic nerve damage distinguishes these injuries from other complications that may resolve after discontinuing medication
The drug owner choosing Stevanato as a supplier , which is highly plausible given the existing oligopoly and Stevanatos value proposition
I see patients rationing their medication, taking half doses just to keep some level of the drug in their system rather than stopping cold turkey
Compounded semaglutide through PlexusDx removes this barrier: no insurance pre-authorization delays, no deductibles, and direct transparent pricing
